Molidustat in Cats

Molidustat is an oral prescription medication used in cats to control nonregenerative anemia linked to chronic kidney disease, or CKD. In the United States, it is marketed as Varenzin-CA1 and is conditionally approved by the FDA for this feline use. That matters because anemia is common in cats with CKD, and it can add to weakness, poor appetite, faster heart rate, and lower quality of life.

In cats with CKD, the kidneys may not make enough erythropoietin, the hormone that signals the body to produce red blood cells. When that happens, the cat can develop a low packed cell volume or hematocrit without the bone marrow responding strongly enough. Molidustat is designed to help the body increase its own erythropoietin production rather than replacing it with an injectable hormone.

This medication is not a fit for every anemic cat. Your vet first needs to confirm that the anemia is nonregenerative and tied mainly to CKD, not blood loss, iron deficiency, inflammation, cancer, hemolysis, FeLV, or another cause. In practice, molidustat is one option within a broader care plan that may also include kidney-supportive diets, anti-nausea treatment, appetite support, blood pressure management, iron assessment, and repeat lab monitoring.

Because Varenzin-CA1 has conditional approval, it has met FDA standards for safety and a reasonable expectation of effectiveness, but full effectiveness data are still being completed. That does not mean it is experimental in the casual sense. It means your vet should use it thoughtfully, with follow-up bloodwork and blood pressure checks to make sure the response is helpful and safe.

Molidustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor, often shortened to HIF-PH inhibitor. In plain language, it changes how the body senses oxygen availability. By blocking this enzyme, the drug stabilizes hypoxia-inducible factor, which then promotes the body’s own erythropoietin production. That can encourage the bone marrow to make more red blood cells.

This is different from darbepoetin, another medication your vet may discuss for CKD-related anemia. Darbepoetin is an injectable erythropoiesis-stimulating agent that acts more directly like erythropoietin. Molidustat, by contrast, is given by mouth and works upstream through the HIF pathway. For some pet parents, the oral route is a practical advantage, especially when giving injections at home would be stressful.

The goal is not to push the red blood cell count as high as possible. The goal is to improve anemia enough to support comfort and daily function while avoiding overcorrection. If hematocrit or packed cell volume rises too far, blood can become too concentrated, which may increase the risk of complications. That is why treatment cycles, pause periods, and monitoring are built into how your vet uses this medication.

Molidustat may also affect other lab values during treatment. In safety data reviewed by the FDA, mild increases in creatinine and phosphorus were seen and generally returned toward baseline after the medication was stopped. Your vet will interpret those changes in the context of your cat’s kidney disease stage, hydration, blood pressure, and overall trend rather than looking at one number alone.

The most commonly reported side effect with molidustat in cats is vomiting. Some cats also have decreased appetite. If vomiting happens when the medication is given on an empty stomach, your vet may advise giving future doses with food, but the medication should still be dosed exactly as directed and not mixed into food unless your vet specifically says that is acceptable. If vomiting continues, your vet should know.

Blood pressure is another important concern. Increases in systolic blood pressure were observed in studies, and cats with CKD may already be prone to hypertension. Your vet may recommend blood pressure checks before starting treatment and during follow-up visits. This is especially important if your cat already has retinal disease, a heart murmur, neurologic signs, or known hypertension.

More serious but less common concerns include thromboembolism, meaning a blood clot, and possible seizure risk in cats with a history of seizures or a predisposition to them. Merck advises caution in cats with seizure history or thromboembolic risk. Overcorrection of anemia can also lead to polycythemia, where the red blood cell level becomes too high, so treatment should not continue beyond the labeled cycle without reassessment.

In FDA-reviewed safety data, mild treatment-associated increases in serum creatinine and phosphorus were noted and generally returned toward baseline after treatment stopped. That does not automatically mean the medication is harming the kidneys, but it does mean lab monitoring matters. See your vet immediately if your cat develops collapse, open-mouth breathing, sudden hind-limb weakness, severe vomiting, marked lethargy, or neurologic changes while taking molidustat.

The labeled conditional dose for cats is 5 mg/kg by mouth once daily for up to 28 consecutive days. Treatment may be repeated after a minimum 7-day pause. Merck also notes that packed cell volume should be monitored during the pause, and another cycle may be considered when the value drops below the target your vet is using. Your vet will decide whether your cat is a candidate for another round based on response, blood pressure, kidney values, and overall stability.

Molidustat is supplied as an oral suspension and should be shaken well before use. VCA advises giving it directly into the cat’s mouth with the provided syringe rather than placing it in food. It can be given with or without food. If stomach upset occurs, your vet may suggest giving it with a small meal or treat. Accurate dosing matters, so pet parents should use only the measuring device supplied with the medication unless your vet provides another plan.

This is not a medication to start, stop, or adjust on your own. Before prescribing it, your vet usually confirms CKD, documents nonregenerative anemia on bloodwork, and looks for other contributors such as iron deficiency, inflammation, gastrointestinal blood loss, or infectious disease. If a cat does not respond as expected, your vet may revisit the diagnosis instead of continuing the same plan.

Monitoring is a core part of treatment. Follow-up often includes repeat CBC or PCV checks, blood pressure measurement, and kidney chemistry review. Those visits help your vet decide whether the medication is helping, whether the pause should continue, and whether another option like iron support, darbepoetin, transfusion, or a different CKD management plan makes more sense for your cat.

Molidustat can interact with several oral products commonly used in cats with kidney disease. VCA lists caution with oral medications containing aluminum, calcium, iron, zinc, or magnesium. That matters because many CKD cats take phosphate binders, supplements, or antacids that contain one or more of these minerals. These products may affect how molidustat is handled in the body or complicate the treatment plan.

Phosphate-binding agents such as lanthanum or sevelamer are also listed as medications to use with caution. Since phosphate control is a routine part of CKD care, your vet may need to stagger medications or decide which therapies matter most at a given stage. Do not change timing on your own, because the best schedule depends on the exact products, your cat’s appetite pattern, and current lab values.

Other erythropoiesis-stimulating agents, including darbepoetin, should also be used cautiously with molidustat. In most cases, these drugs are not used casually together. If your cat has already been treated with darbepoetin or epoetin-type therapy, your vet will decide whether to transition, pause, or stay with the current approach.

Because many cats with CKD take several medications at once, it is smart to bring a full list to every visit. Include prescription drugs, compounded medications, supplements, probiotics, phosphate binders, antacids, and anything added to food. That gives your vet the best chance to build a practical schedule and reduce avoidable interactions.